Apollomics Inc. Class A Ordinary Shares Total Liabilities
Apollomics Inc. Class A Ordinary Shares total liabilities. Based on the latest financial reports, Apollomics Inc. Class A Ordinary Shares (APLM) has total liabilities worth $9.90 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Apollomics Inc. Class A Ordinary Shares (APLM) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Apollomics Inc. Class A Ordinary Shares (2019–2025)
Total liabilities of Apollomics Inc. Class A Ordinary Shares from 2019 to 2025. This chart illustrates how Apollomics Inc. Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Explore APLM long-term investment intensity to see how much of total assets are deployed in long-term investments.
Apollomics Inc. Class A Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Apollomics Inc. Class A Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WebCash Corporation
KQ:053580
|
Korea | ₩20.23 Billion |
|
Alakasa Industrindo Tbk
JK:ALKA
|
Indonesia | Rp12.86 Billion |
|
Malin Corporation plc
IR:MLC
|
Ireland | €5.30 Million |
|
Molinos Juan Semino SA
BA:SEMI
|
Argentina | AR$16.23 Billion |
|
E&E Recycling
TWO:8440
|
Taiwan | NT$165.55 Million |
|
Scanwolf Corporation Bhd
KLSE:7239
|
Malaysia | RM135.22 Million |
|
KCP Sugar and Industries Corporation Limited
NSE:KCPSUGIND
|
India | Rs-4.60 Billion |
|
JAS Asset PCL
BK:J
|
Thailand | ฿3.18 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Apollomics Inc. Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Apollomics Inc. Class A Ordinary Shares asset portfolio.
Liquidity & Leverage Metrics
Apollomics Inc. Class A Ordinary Shares Total Liabilities Ratios Explained
Apollomics Inc. Class A Ordinary Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apollomics Inc. Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apollomics Inc. Class A Ordinary Shares (2019–2025)
The table below shows the annual total liabilities of Apollomics Inc. Class A Ordinary Shares from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.90 Million | +20.26% |
| 2024-12-31 | $8.23 Million | -41.82% |
| 2023-12-31 | $14.15 Million | -97.30% |
| 2022-12-31 | $524.60 Million | +55.99% |
| 2021-12-31 | $336.30 Million | +12.90% |
| 2020-12-31 | $297.87 Million | +113.11% |
| 2019-12-31 | $139.78 Million | -- |
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more